menu
    • menu
    [{"orgOrder":0,"company":"Lisata Therapeutics","sponsor":"University of Cincinnati","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Agreement","leadProduct":"Certepetide","moa":"||Alpha-5 integrin","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Discovery","graph3":"Lisata Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lisata Therapeutics \/ University of Cincinnati","highestDevelopmentStatusID":"2","companyTruncated":"Lisata Therapeutics \/ University of Cincinnati"},{"orgOrder":0,"company":"Nuvisan GmbH","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Discovery","graph3":"Nuvisan GmbH","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Nuvisan GmbH \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Nuvisan GmbH \/ Bill & Melinda Gates Foundation"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lisata Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Lisata Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certepetide,Bevacizumab

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Discovery

                            Sponsor : University of Cincinnati

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Lisata And Cincinnati University to Research Certepetide for Endometriosis

                            Details : Through the agreement, Lisata will evaluate a novel cyclic peptide product candidate, LSTA1 (certepetide), in combination with bevacizumab to treat endometriosis.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            October 28, 2024

                            Lead Product(s) : Certepetide,Bevacizumab

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Discovery

                            Sponsor : University of Cincinnati

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nuvisan GmbH

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Nuvisan GmbH

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Discovery

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : $9.6 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            NUVISAN Receives US$9.6M Grant for A Multi-Target Drug Discovery Program on Novel Non-Hormonal Contraceptive M...

                            Details : The comapany will use the received grant for an integrated program on discovery and early development of novel non-hormonal contraceptive medicines and further optimize the hits to in vivo lead compounds during the hit-to-lead process.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 20, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Discovery

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : $9.6 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Celmatix

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Celmatix

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Discovery

                            Sponsor : Evotec

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Evotec Partner Celmatix Achieves Milestone For PCOS Drug Programme

                            Details : Novel PCOS drug target, is largely unknown, genomic studies suggest a strong genetic connection from Celmatix-Evotec Alliance, identified by Celmatix, progresses into hit-identification.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 18, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Discovery

                            Sponsor : Evotec

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth